Axsome Therapeutics (AXSM) News Today → Millionaire investor and Republican donor makes surprising election prediction (From InvestorPlace) (Ad) Free AXSM Stock Alerts $75.64 +3.14 (+4.33%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11 at 10:00 AM | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 11 at 9:00 AM | fool.comPrediction: These 2 Growth Stocks Could Triple By 2030May 11 at 4:37 AM | marketbeat.com21,086 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Truist Financial CorpTruist Financial Corp purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 21,086 shares of the company's stock, valued at approximateMay 11 at 2:30 AM | americanbankingnews.comHC Wainwright Research Analysts Cut Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM)May 10 at 7:55 AM | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q2 2024 Earnings of ($1.31) Per Share, HC Wainwright ForecastsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for Axsome Therapeutics in a research note issued on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per shaMay 10 at 6:31 AM | seekingalpha.comWhy Axsome Therapeutics Is A Promising Stock Pick In CNS TreatmentsMay 10 at 4:36 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) PT Lowered to $106.00May 10 at 4:02 AM | americanbankingnews.comHC Wainwright Weighs in on Axsome Therapeutics, Inc.'s Q3 2025 Earnings (NASDAQ:AXSM)May 10 at 3:12 AM | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 10 at 2:18 AM | americanbankingnews.comQ2 2024 Earnings Forecast for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Issued By William BlairMay 10 at 2:18 AM | americanbankingnews.comAxsome Therapeutics, Inc. to Post Q2 2024 Earnings of ($1.46) Per Share, Leerink Partnrs Forecasts (NASDAQ:AXSM)May 9, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q3 2025 Earnings of $0.47 Per Share, HC Wainwright ForecastsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at HC Wainwright dropped their Q3 2025 EPS estimates for shares of Axsome Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.47 fMay 9, 2024 | americanbankingnews.comLeerink Partnrs Comments on Axsome Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:AXSM)May 8, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $106.00 at MizuhoMizuho lowered their price target on shares of Axsome Therapeutics from $109.00 to $106.00 and set a "buy" rating on the stock in a report on Wednesday.May 8, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical TrialsMay 8, 2024 | marketbeat.comFY2026 EPS Estimates for Axsome Therapeutics, Inc. Reduced by Analyst (NASDAQ:AXSM)Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for Axsome Therapeutics in a report released on Monday, May 6th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn $1.May 8, 2024 | globenewswire.comAxsome Therapeutics to Present at Upcoming Investor ConferencesMay 8, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Given Buy Rating at HC WainwrightMay 8, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $112.00 at Robert W. BairdMay 8, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $125.00 by Analysts at CitigroupMay 7, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) PT Lowered to $125.00Citigroup cut their target price on Axsome Therapeutics from $127.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic PositioningMay 7, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $190.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday.May 7, 2024 | marketbeat.comRobert W. Baird Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $112.00Robert W. Baird boosted their price target on Axsome Therapeutics from $108.00 to $112.00 and gave the stock an "outperform" rating in a research report on Tuesday.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion PotentialMay 7, 2024 | finance.yahoo.comAxsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...May 7, 2024 | finance.yahoo.comQ1 2024 Axsome Therapeutics Inc Earnings CallMay 6, 2024 | fool.comAxsome Therapeutics (AXSM) Q1 2024 Earnings Call TranscriptMay 6, 2024 | investorplace.comAXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | washingtonpost.comAxsome: Q1 Earnings SnapshotMay 6, 2024 | msn.comAxsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15MMay 6, 2024 | globenewswire.comAxsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | stocknews.comInvestors Beware of These 3 Pharma StocksMay 2, 2024 | marketbeat.comCannell & Co. Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Cannell & Co. lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,845 shares of the company's stock after selling 21,345 shares during the period. CannellMay 1, 2024 | globenewswire.comAxsome Therapeutics Recognizes May as Mental Health Awareness MonthApril 30, 2024 | investorplace.com3 Biotech Stocks with Blockbuster Drug Pipelines: April EditionApril 29, 2024 | finance.yahoo.comGinkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of DirectorsApril 29, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Up to $71.71Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Up to $71.71April 29, 2024 | markets.businessinsider.comBuy Rating on Axsome Therapeutics Amidst Strong Auvelity Performance and Positive Revenue ProspectsApril 29, 2024 | msn.comAxsome Therapeutics stock rises on upgrade to Overweight at Morgan StanleyApril 29, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Axsome Therapeutics Through Analyst InsightsApril 29, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Rating Increased to Overweight at Morgan StanleyMorgan Stanley upgraded shares of Axsome Therapeutics from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $90.00 to $115.00 in a report on Monday.April 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics Amidst Anticipated Clinical Data and Resilient Product PerformanceApril 19, 2024 | marketbeat.comBrokers Offer Predictions for Axsome Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:AXSM)Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at William Blair lifted their Q1 2024 earnings estimates for shares of Axsome Therapeutics in a research note issued to investors on Wednesday, April 17th. William Blair analyst M. Minter now anticipates that the company willApril 18, 2024 | markets.businessinsider.comStrong Buy on Axsome’s Auvelity Amidst Competitive MDD MarketApril 16, 2024 | markets.businessinsider.comAuvelity’s Strong Performance Sustains Buy Rating for Axsome TherapeuticsApril 15, 2024 | marketbeat.comPhocas Financial Corp. Acquires New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Phocas Financial Corp. bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 26,890 shares of the company's stock, valued at approximately $2,140,000. Phocas FinanciaApril 15, 2024 | globenewswire.comAxsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Have you heard of the $11 AI Coin? (Ad)A new set of AI startups are rising... Except you won't find them on the stock market. Find out more about this $11 AI Coin right now AXSM Media Mentions By Week AXSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.050.58▲Average Medical News Sentiment AXSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼526▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BHVN News SMMT News CRNX News RARE News PBH News INSM News HCM News XENE News ALKS News PRGO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
